L-gamma-谷氨酰-S-癸基-L-半胱氨酰甘氨酸 | 102814-04-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: L-gamma-谷氨酰-S-癸基-L-半胱氨酰甘氨酸
• 中文别名: 1-(4-氨基-1,2,5-恶二唑-3-基)-5-甲基-1H-1,2,3-三唑-4-羧酸乙酯
• 英文名称: S-Decylglutathione
• 英文别名: (2S)-2-amino-5-[[(2R)-1-(carboxymethylamino)-3-decylsulfanyl-1-oxopropan-2-yl]amino]-5-oxopentanoic acid
• CAS: 102814-04-0
• 化学式: C₂₀H₃₇N₃O₆S
• 分子量: 447.6
• InChiKey: XAAOGZMKEJNHLW-HOTGVXAUSA-N

物化性质

• 沸点：
  758.9±60.0 °C(Predicted)
• 密度：
  1.183±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  30
• 可旋转键数：
  19
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  184
• 氢给体数：
  5
• 氢受体数：
  8

安全信息

• WGK Germany：
  3
• 海关编码：
  2930909090

文献信息

• Targeted liposomal delivery of cGMP analogues
  申请人：Mireca Medicines GmbH

  公开号：US10322087B2

  公开（公告）日：2019-06-18

  The invention relates to means and methods of targeted drug delivery of therapeutic agent to and across the blood-ocular barrier. In particular, the invention relates to cyclic guanosine-3′, 5′-monophosphate analogs as therapeutic agent for treating retinal diseases. The cGMPSs targeted to the blood-ocular barrier by glutathione-based ligands that facilitate the specific binding to and enhanced internalization by glutathione transporters present on the blood-ocular barrier. The glutathione-based ligands are conjugated to nanocontainers such as liposomes encapsulating the cGMPSs.

  本发明涉及将治疗剂靶向输送到血眼屏障并穿过血眼屏障的手段和方法。特别是，本发明涉及环鸟苷-3′，5′-单磷酸类似物作为治疗视网膜疾病的治疗剂。环鸟苷-3′，5′-单磷酸类似物通过谷胱甘肽配体靶向血眼屏障，促进与存在于血眼屏障上的谷胱甘肽转运体的特异性结合和增强内化。谷胱甘肽配体与包裹 cGMPSs 的脂质体等纳米容器共轭。
• Treatment of dandruff
  申请人：Unilever Home & Personal Care USA, Division of Conopco, Inc.

  公开号：US20020168327A1

  公开（公告）日：2002-11-14

  Dandruff and symptoms of dandruff can be treated using lipophilic agents or lipid precursor and/or promoters to strengthen the scalp. The lipophilic agents or lipid precursor and/or promoters are preferably used in conjunction with an antifungal agent which has activity against Malassezia spp, particularly Malassezia furfur . Suitable antifungal agents include those conventionally used for the treatment of dandruff including, for example, zinc pyrithrone (ZnPTO), octopirox and azole antifungal agents such as climbazole and ketocanazole. The antifungal agents may be used singularly or as a mixture of one or more antifungal agents.

  头皮屑和头皮屑症状可使用亲脂剂或脂质前体和/或促进剂来治疗，以增强头皮的功效。亲脂剂或脂质前体和/或促进剂最好与具有抗马拉色菌活性的抗真菌剂一起使用，特别是 糠秕马拉色菌 .合适的抗真菌剂包括传统上用于治疗头皮屑的抗真菌剂，例如吡蚜酮锌 (ZnPTO)、辛吡罗和唑类抗真菌剂，如爬山唑和酮康唑。这些抗真菌剂可单独使用，也可作为一种或多种抗真菌剂的混合物使用。
• Polymorphisms in the human gene for the multidrug resistance-associated protein 1 (MRP-1) and their use in diagnostic and therapeutic applications
  申请人：——

  公开号：US20040161768A1

  公开（公告）日：2004-08-19

  The present invention relates to a polymorphic MRP-1 polynucleotide. Moreover, the invention relates to genes or vectors comprising the polynucleotides of the invention and to a host cell genetically engineered with the polynucleotide or gene of the invention. Further, the invention relates to methods for producing molecular variant polypeptides or fragments thereof, methods for producing cells capable of expressing a molecular variant polypeptide and to a polypeptide or fragment thereof encoded by the polynucleotide or the gene of the invention or which is obtainable by the method or from the cells produced by the method of the invention. Furthermore, the invention relates to an antibody which binds specifically the polypeptide of the invention. Moreover, the invention relates to a transgenic non-human animal. The invention also relates to a solid support comprising one or a plurality of the above mentioned polynucleotides, genes, vectors, polypeptides, antibodies or host cells. Furthermore, methods of identifying a polymorphism, identifying and obtaining a pro-drug or drug or an inhibitor are also encompassed by the present invention. In addition, the invention relates to methods for producing of a pharmaceutical composition and to methods of diagnosing a disease. Further, the invention relates to a method of detection of the polynucleotide of the invention. Furthermore, comprised by the present invention are a diagnostic and a pharmaceutical composition. Even more, the invention relates to uses of the polynucleotides, genes, vectors, polypeptides or antibodies of the invention. Finally, the invention relates to a diagnostic kit.

  本发明涉及一种多态 MRP-1 多核苷酸。此外，本发明还涉及包含本发明多核苷酸的基因或载体，以及用本发明多核苷酸或基因进行遗传工程的宿主细胞。此外，本发明还涉及生产分子变异多肽或其片段的方法、生产能够表达分子变异多肽的细胞的方法以及由本发明多核苷酸或基因编码的多肽或其片段，或可通过本发明方法获得或从本发明方法生产的细胞中获得的多肽或其片段。此外，本发明还涉及一种能特异性结合本发明多肽的抗体。此外，本发明还涉及一种转基因非人类动物。本发明还涉及一种包含一种或多种上述多核苷酸、基因、载体、多肽、抗体或宿主细胞的固体支持物。此外，本发明还包括鉴定多态性、鉴定和获得原药或药物或抑制剂的方法。此外，本发明还涉及药物组合物的生产方法和疾病诊断方法。此外，本发明还涉及本发明多核苷酸的检测方法。此外，本发明还包括一种诊断方法和一种药物组合物。此外，本发明还涉及本发明的多核苷酸、基因、载体、多肽或抗体的用途。最后，本发明还涉及一种诊断试剂盒。
• Liposomes for protection against toxic compounds
  申请人：Awasthi Sanjay

  公开号：US20050123594A1

  公开（公告）日：2005-06-09

  Generally, and in one form, the present invention is a method of method of preparing a proteoliposome comprising the step of contacting a liposome with an effective portion of RLIP76 to create a proteoliposome. In another form, the present invention is a proteoliposomal composition comprising a liposome and an effective portion of RLIP76. In yet another form, the present invention is a kit for reducing the concentration of toxic compounds and their by-products comprising an effective dose of a proteoliposome, wherein the proteoliposome is a liposome and an effective portion of RLIP76 and an instructional pamphlet. Applications of the present invention include the protection and treatment of mammals and the environment against the accumulation of toxic compounds. The present invention prevents accumulation of one or more toxic compounds, reduces the concentration of toxic compounds, and protects against further contamination with one or more toxic compounds.

  一般来说，在一种形式中，本发明是一种制备蛋白脂质体的方法，包括将脂质体与有效部分的RLIP76接触以产生蛋白脂质体的步骤。在另一种形式中，本发明是一种蛋白脂质体组合物，包括脂质体和有效部分的 RLIP76。在另一种形式中，本发明是一种用于降低有毒化合物及其副产物浓度的试剂盒，包括有效剂量的蛋白脂质体，其中蛋白脂质体是脂质体和有效部分的 RLIP76 以及说明书。本发明的应用包括保护和治疗哺乳动物和环境，防止有毒化合物的积累。本发明可防止一种或多种有毒化合物的积累，降低有毒化合物的浓度，并防止进一步受到一种或多种有毒化合物的污染。
• DIETARY SUPPLEMENTS COMPRISING VITAMINS AND MINERALS
  申请人：LifeScience Corporation

  公开号：EP0514451B1

  公开（公告）日：1997-01-15